November 12th, 2011 by JessicaBerthold in Research
No Comments »
“Wow, Celexa?”
“Yeah, who knew?”
I overheard this conversation in the ladies’ room immediately after a session speaker advised treating agitation and aggression in dementia with citalopram. Indeed, there was a bit of a murmur in the audience when Dr. Aleta Borrud made the suggestion during her talk at the Mayo Update in Hospital Medicine 2011 course.
Part of the reason for the reaction may be– as a physician I spoke with noted– that Read more »
*This blog post was originally published at ACP Hospitalist*
October 26th, 2011 by PeterWehrwein in Research
No Comments »
Remember when the best-selling book Listening to Prozac came out almost 20 years ago?
Now Americans aren’t just reading about Prozac. They are taking it and other antidepressants (Celexa, Effexor, Paxil, Zoloft, to name just a few) in astounding numbers.
According to a report released yesterday by the National Center for Health Statistics (NCHS), the rate of antidepressant use in this country among teens and adults (people ages 12 and older) increased by almost 400% between 1988–1994 and 2005–2008.
The federal government’s health statisticians figure that Read more »
*This blog post was originally published at Harvard Health Blog*
January 23rd, 2011 by Peggy Polaneczky, M.D. in Opinion, Research
No Comments »
In a well done placebo-controlled study published in this week’s Journal of the American Medical Association (JAMA), use of escitalopram (Lexapro) reduced hot flashes in menopausal women.
Investigators enrolled 205 women, randomizing them to either Lexapro 10 mg or placebo, with instructions to increase to two pills a day if needed after four weeks. Lexapro users experienced about a 60 percent reduction in hot flash frequency over the eight-week study. About half ended up on the larger 20 mg daily dose by study’s end. The drug’s effect was apparent at about one week of use, and it was well tolerated.
As in almost studies of menopausal treatments, the placebo group also experienced a significant reduction in symptoms — about 40 percent — but the difference between placebo and drug groups was significant. Compared to placebo users, Lexapro users had a bigger rebound of symptoms when stopping their treatment, were more satisfied, and more likely to want to continue the study drug, another validation of the drug’s efficacy. Read more »
*This blog post was originally published at tbtam*
